Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Iloprost Clear all
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 19, 2026, 6:20 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude

NCT00708565
View directory record Official record
Conditions
Hypoxic Pulmonary Vasoconstriction
Interventions
iloprost
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
18 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 19, 2026, 6:20 AM EDT
Terminated Phase 4 Interventional Results available

Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension

NCT03044314
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Iloprost and nitric oxide administration
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 19, 2026, 6:20 AM EDT
Terminated Phase 4 Interventional

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

NCT00409526
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Inhaled Iloprost
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 7 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 4 Interventional

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

NCT00403650
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 19, 2026, 6:20 AM EDT
Completed No phase listed Observational

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

NCT01389206
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 19, 2026, 6:20 AM EDT
Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT00086463
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
Interventions
Iloprost or placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2011 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional

Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

NCT01941225
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Inhaled iloprost 5.0 mcg, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

NCT03867097
View directory record Official record
Conditions
Raynaud Phenomenon Secondary to Systemic Sclerosis
Interventions
Placebo IV infusion, Iloprost Injection, for intravenous use
Drug
Lead sponsor
Civi Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 1 Interventional

Iloprost in Preventing Lung Cancer in Former Smokers

NCT02237183
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Iloprost, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 19, 2026, 6:20 AM EDT
Terminated Not applicable Interventional Results available

Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

NCT01319045
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome
Interventions
Iloprost
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

NCT00109681
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Iloprost Inhalation Solution (Ventavis)
Drug
Lead sponsor
Actelion
Industry
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 19, 2026, 6:20 AM EDT
Terminated Phase 2 Interventional Results available

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

NCT00467896
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Iloprost PD-6, Iloprost PD-15
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

NCT04040322
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Placebo IV infusion, Iloprost Injection, for intravenous use
Drug
Lead sponsor
Civi Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Not applicable Interventional

Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)

NCT00561223
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Interventions
iloprost Inhalation, iloprost
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Early Phase 1 Interventional

Inhaled Iloprost in Mild Asthma

NCT01209533
View directory record Official record
Conditions
Asthma
Interventions
Iloprost
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 4 Interventional Results available

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

NCT00741819
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 19, 2026, 6:20 AM EDT
Not listed No phase listed Observational

Enhanced Assisted Reproductive Technology Pregnancy Rate by Prostacyclin Analog (Iloprost)

NCT01549171
View directory record Official record
Conditions
Pregnancy
Interventions
Iloprost, normal saline
Drug · Other
Lead sponsor
Fertility Specialists of Houston
Other
Eligibility
20 Years to 39 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 19, 2026, 6:20 AM EDT
Terminated Phase 4 Interventional

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

NCT00458042
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2007 · Synced Oct 19, 2026, 6:20 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension

NCT00453414
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Iloprost Inhalation Solution (Ventavis)
Drug
Lead sponsor
Actelion
Industry
Eligibility
3 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Denver, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 19, 2026, 6:20 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude

NCT00724321
View directory record Official record
Conditions
Hypoxic Pulmonary Vasoconstriction
Interventions
iloprost
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 1 Interventional

Iloprost Effects on Gas Exchange and Pulmonary Mechanics

NCT01274481
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury, Pulmonary Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 19, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

NCT00084409
View directory record Official record
Conditions
Lung Cancer, Precancerous Condition
Interventions
iloprost, placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
6
States / cities
Aurora, Colorado • Denver, Colorado • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 19, 2026, 6:20 AM EDT